# Ligand-specific activation trajectories dictate GPCR signalling in cells

## TL;DR

This study shows that different agonists activate the M2 muscarinic receptor in distinct ways, leading to multiple active states with varying abilities to trigger G-protein signaling in living cells.

## Contribution

The study reveals that ligand-specific activation trajectories and conformational equilibria underlie GPCR signaling in intact cells.

## Key findings

- Different agonists produce at least four distinct active states of the G-protein-bound M2R.
- Each active state has a different ability to activate G proteins.
- Activation trajectories involve both common and ligand-specific conformational changes.

## Abstract

G-protein-coupled receptors (GPCRs) are key mediators of cell communication and represent the most important class of drug targets1,2. Biophysical studies with purified GPCRs in vitro have suggested that they exist in an equilibrium of distinct inactive and active states, which is modulated by ligands in an efficacy-dependent manner3–11. However, how efficacy is encoded and whether multiple receptor states occur in living cells remain unclear. Here we use genetic code expansion12 and bioorthogonal labelling13–16 to generate a panel of fluorescence-based biosensors for a prototypical GPCR, the M2 muscarinic acetylcholine receptor (M2R). These biosensors enable real-time monitoring of agonist-promoted conformational changes across the receptor’s extracellular surface in intact cells. We demonstrate that different agonists produce equilibria of at least four distinct active states of the G-protein-bound M2R, each with a different ability to activate G proteins. The formation of these M2R–G-protein complexes occurs over 0.2–5 s along trajectories that involve both common and ligand-specific conformational changes and appear to determine G-protein selectivity. These observations reveal the molecular nature of ligand efficacy in intact cells. Selectively exploiting such different GPCR activation trajectories and conformational equilibria may open new avenues for GPCR drug discovery.

Different agonists produce equilibria of at least four distinct active states of the G-protein-bound M2 muscarinic acetylcholine receptor, each with a different ability to activate G proteins.